Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses
Conditions: HIV Infections; HBV Coinfection Interventions: Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI; Drug: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) Sponsors: ANRS, Emerging Infectious Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants
Condition: Healthy Interventions: Drug: DRV/COBI FDC; Drug: COBI; Drug: DRV Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 18, 2022 Category: Research Source Type: clinical trials
A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children
Condition: Human Immunodeficiency Virus (HIV) Intervention: Drug: DRV/COBI FDC Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2022 Category: Research Source Type: clinical trials
A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions
Condition: Healthy Interventions: Drug: Darunavir; Drug: Cobicistat; Drug: Darunavir/Cobicistat FDC Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials
